The industry group MassBio has released its annual temperature check on the biotech industry in Massachusetts, and the results are grim.

Both public and private funding have plummeted as federal policy changes have thrown the biotech sector into an era of uncertainty. Venture capital investment in Massachusetts-based companies dropped more than 17% to $2.75 billion in the first half of 2025, compared to the same period in 2024, the lowest level since 2017.

Massachusetts is also projected to receive around $463 million less in National Institutes of Health funding this year than it did in 2024, according to MassBio, a trade and lobbying organization for the life sciences industry.

To read the rest of this story subscribe to STAT+. Subscribe Log In

See Full Page